Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zasocitinib - Takeda

Next Previous
X
Search
Drug Profile

Zasocitinib - Takeda

Alternative Names: NDI-034858; Small molecule TYK2 inihibitor - Nimbus Therapeutics; TAK-279

Latest Information Update: 16 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nimbus Therapeutics
  • Developer Nimbus Therapeutics; Takeda
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Erythrodermic psoriasis; Plaque psoriasis; Pustular psoriasis
  • Phase II Crohn's disease; Psoriatic arthritis; Ulcerative colitis

Most Recent Events

  • 12 Aug 2024 Takeda plans a phase III trial for Plaque psoriasis in November 2024 (PO) (NCT06550076) (EUCT2024-512496-12)
  • 04 Aug 2024 Takeda completes a phase I trial in Plaque psoriasis (In volunteers) in China (PO) (NCT06111547)
  • 26 Jun 2024 Adhoc HVP review - corrected intro, rearranged KDM data, added phase I DEV line for autoimmune disorder in dormant record since it was redundant, unpublished NDR HE, corrected FET's, rearranged clinical data according to phase, sent thes request to update DC

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top